Bioventus Inc
$ 10.56
6.56%
15 Apr - close price
- Market Cap 634,607,000 USD
- Current Price $ 10.56
- High / Low $ 10.57 / 10.12
- Stock P/E 28.55
- Book Value 2.74
- EPS 0.33
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.13 %
- 52 Week High 10.57
- 52 Week Low 5.81
About
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$14.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 | 2023-05-16 |
| Reported EPS | 0.24 | 0.15 | 0.21 | -0.0399 | 0.15 | 0.06 | 0.19 | 0.07 | 0.07 | 0.05 | 0.14 | -0.26 |
| Estimated EPS | 0.2042 | 0.11 | 0.21 | 0.0228 | 0.085 | 0.03 | 0.07 | -0.07 | 0.02 | -0.02 | 0.03 | -0.15 |
| Surprise | 0.0358 | 0.04 | 0 | -0.0627 | 0.065 | 0.03 | 0.12 | 0.14 | 0.05 | 0.07 | 0.11 | -0.11 |
| Surprise Percentage | 17.5318% | 36.3636% | 0% | -275% | 76.4706% | 100% | 171.4286% | 200% | 250% | 350% | 366.6667% | -73.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BVS
2026-04-15 22:09:16
Bioventus Inc.'s Senior Vice President and CFO, Mark Leonard Singleton, exercised 13,000 restricted stock units (RSUs) on April 10, 2026, receiving an equal number of Class A shares. To cover tax obligations, 5,648 Class A shares were withheld at a price of $9.06 per share in a non-market transaction. Following these transactions, Singleton directly owns 182,981 Class A shares, indicating a net increase in his equity position.
2026-04-15 01:09:16
This article reports on an insider trading activity for Bioventus Inc. (BVS) where Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026. She received 4,300 shares of Class A common stock and 1,868 shares were withheld to cover tax obligations. Post-transaction, her direct ownership increased to 64,164 shares, reflecting a routine equity compensation event rather than a discretionary market trade.
2026-04-14 22:09:16
Anthony D'Adamio, SVP & General Counsel of Bioventus Inc. (BVS), exercised 9,925 restricted stock units (RSUs) on April 10, 2026, converting them into 9,925 shares of Class A common stock. To cover tax obligations, 4,312 shares were disposed of at $9.06 per share through a tax-withholding transaction, not an open-market sale. Following these transactions, D'Adamio directly holds 153,655 shares of Class A common stock.
2026-03-25 21:09:09
Mark Leonard Singleton, CFO of Bioventus Inc. (BVS), exercised 18,625 Restricted Stock Units (RSUs) on March 20, 2026. For tax purposes related to this vesting, 8,091 shares were withheld at a price of $8.64 per share. Following these transactions, Singleton directly holds 169,981 shares of Bioventus Class A common stock.
2026-03-17 21:09:05
Bioventus Inc. CEO Robert E. Claypoole reported significant equity compensation changes in a recent SEC filing. On March 13, 2026, he exercised 33,500 restricted stock units, leading to 14,553 shares being withheld for tax obligations, leaving him with 135,944 Class A shares. Additionally, he received new grants of 278,000 restricted stock units and 309,000 stock options, which will vest over four years subject to his continued service.
2026-03-17 21:09:05
Bioventus Inc. CFO Mark Leonard Singleton reported significant equity compensation activities, including receiving 104,000 restricted stock units and an option for 116,000 shares on March 13, 2026. He also exercised 13,500 RSUs, with some shares withheld for tax purposes, bringing his direct holdings to 159,447 shares of Class A common stock. These awards and options are subject to a four-year vesting schedule tied to his continued service.
